Biology subjects

Tondi, D.

Publications and source records attributed to Tondi, D..

3 recordsLinked to original sources

bioRxiv2026

Rt3DE-based finite element analysis of functional tricuspid regurgitation and RV free wall approximation

PurposeFunctional tricuspid regurgitation (FTR) is driven by right ventricular (RV) remodeling, annular dilation, and papillary muscle dislocation. Free wall approximation (FWA) has been proposed to treat FTR by addressing RV dilation, but its effects on tricuspid valve (TV) biomechanics remain unclear. We present a real-time 3D echocardiographic (rt3DE)-based finite element framework to quantify TV biomechanics under FTR, and preliminarily apply it to assess FWA effects. MethodsSubject-specific models were developed from rt3DE data of three dilated porcine hearts in an ex-vivo mock-loop. TV geometries at end-diastole and peak systole (PS) were complemented by parametric chordae tendineae and hyperelastic tissue properties. TV closure was simulated under a standard pressure load and image-based annular motion. After tuning chordae length to replicate the PS ground truth in FTR, FWA was simulated as 30% and 60% approximations along three anatomical directions (anterior-posterior, A-P; anterior-septal, A-S; anterior-septal wall, A-SW). ResultsIn FTR simulations, median geometric errors ranged from 1.16 to 1.26 mm; median stress ranged from 56.4 to 74.7 kPa. FWA simulations predicted regurgitant orifice area (ROA) reductions by 53-99%, albeit overestimating the residual ROA vs. in vitro ground truth when starting from particularly extreme FTR conditions; concomitantly, a median stress reduction by 8-43% vs. FTR conditions was predicted. ConclusionPreliminary data suggest that our rt3DE-based framework can reliably quantify FTR-related TV biomechanics and that post-FWA biomechanics depends on initial FTR conditions. A larger cohort is required to verify the method and obtain statistically significant results.

bioengineering↗

bioRxiv2025

Identification and characterization of a small-molecule inhibitor of the Pseudomonas aeruginosa SOS response

The SOS response is among the most conserved pathways that promote the acquisition of antibiotic resistance in bacteria. This study aimed to identify and characterize small-molecule inhibitors of the SOS response system in the opportunistic pathogen Pseudomonas aeruginosa. A library of 318 drug-like compounds was screened for inhibition of RecA-induced LexA autoproteolysis, a key step in SOS activation. One hit compound, 3-(2-sulfanylanilino)propanoic acid, showed dose-dependent inhibition with an IC50 in the mid-micromolar range. Differential scanning fluorimetry and isothermal titration calorimetry analysis revealed that A12 binds to both RecA and LexA with low micromolar affinity. Mass spectrometry analysis demonstrated that A12 covalently modifies RecA likely via condensation, while it forms a disulfide bond with Cys104 of LexA. Inhibition was diminished under reducing conditions, confirming disulfide formation is crucial for A12 activity. Importantly, A12 did not impair LexAs ability to bind SOS box DNA sequences, which is needed to keep the SOS genes repressed. While A12s potency requires optimization, it represents a promising scaffold for developing anti-SOS compounds targeting P. aeruginosa.

biochemistry↗

bioRxiv2018

In Silico Identification and In Vitro Validation of Novel KPC-2 β-lactamase Inhibitors

Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type {beta}-lactamases are often reported as resistant to available {beta}-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non {beta}-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, as putative hit candidates. We performed a structure-based in silico screening of commercially available compounds for non-{beta}-lactam KPC-2 inhibitors. Thirty-two commercially available high-scoring, fragment-like hits were selected for in vitro validation and their activity and mechanism of action vs the target was experimentally evaluated using recombinant KPC-2. N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluorobenzamide (11a), in light of its ligand efficiency (LE = 0.28 kcal/mol/non-hydrogen atom) and chemistry, was selected as hit to be directed to chemical optimization to improve potency vs the enzyme and explore structural requirement for inhibition in KPC-2 binding site. Further, the compounds were evaluated against clinical strains overexpressing KPC-2 and the most promising compound reduced the MIC of the {beta}-lactam antibiotic meropenem by four fold.

biochemistry↗